Bronchiolitis obliterans syndrome (BOS) remains an important complication following allo-SCT. The development of this condition portends a higher morbidity and mortality but the effect on heath-related quality of life (HRQL) is unknown. The aim of this study was to determine whether the development of BOS impacted HRQL compared with patients without BOS. This Institutional Review Board-approved prospective study analyzed 126 patients who underwent allo-SCT at our institution. Patients were administered three HRQL survey tools (SF-36, European Organization for Research and Treatment of Cancer QLQ-c30 and St George Respiratory Questionnaire (SGRQ)) before transplant and then again at 6 months, 1 year and 2 years after transplant. Patients were analyzed in three groups determined by highest chronic GVHD (cGVHD) severity and BOS status. Overall, our study group had improving HRQL after transplant when measured over time, measured by the SF-36 with stable HRQL, when measured by the SGRQ total score and QLQ-c30. Patients that developed BOS had significantly worse HRQL scores measured by the SGRQ and the SF-36 physical composite score. This difference was not explained by the severity of cGVHD that patients with BOS developed.
INTRODUCTION
Allo-SCT is used to achieve possible cure in a variety of malignant and non-malignant conditions. While overall mortality following SCT is decreasing, 1 pulmonary complications following SCT remain common and contribute to a significant amount of mortality and morbidity. 2 Bronchiolitis obliterans syndrome (BOS) is of particular interest as it remains an important long term pulmonary complication that is associated with high mortality. 2 BOS is a pulmonary manifestation of chronic GVHD (cGVHD) characterized by new airflow obstruction after SCT. 2, 3 It occurs almost exclusively following allogeneic transplantation rather than autologous transplant, which has led to the theory of allorecognition as the etiology. 3 When obtained, pathologic diagnosis is characterized by circumferential fibrosis of the small airways. 4 Clinically, patients present with non-specific pulmonary symptoms including cough, shortness of breath or wheezing. 2 A recent study using a modified National Institute of Health (NIH) consensus definition found the prevalence to be estimated at 5.5% in patients undergoing allogeneic SCT and up to 14% in those with cGVHD. 3 Other studies have found the incidence to be higher, with as many as 26% of patients undergoing transplant with progressive airflow obstruction consistent with BOS. 5 It is important to recognize the impact that the underlying disease and also the treatment have on health-related quality of life (HRQL) in patients undergoing SCT. In general, it has been shown that HRQL following SCT improves over time and reaches at least close to baseline. [6] [7] [8] However, HRQL remains diminished compared with population normals using a variety of assessment tools. [7] [8] [9] [10] There are several factors associated with a worse HRQL including: cGVHD, [11] [12] [13] older age 13 and female sex. 13 To our knowledge, HRQL in patients developing BOS following SCT has not been reported. However, HRQL in patients developing BOS following lung transplantation, which is thought to have similar pathophysiology, has been examined. Multiple studies have shown that the development of BOS has a detrimental effect on HRQL using a variety of assessment tools. [14] [15] [16] [17] It is unknown if this negative HRQL impact is also shared by those developing BOS following SCT. The aim of our study is to determine how BOS following allo-SCT affects HRQL.
MATERIALS AND METHODS

Data collection
All patients who underwent allo-SCT at our institution from February 2006 until April 2011 were eligible for participation in the study. A total of 245 subjects were enrolled after informed consent was obtained. Data were collected as part of an Institutional Review Board-approved single-center, prospective cohort study looking at the development of pulmonary complications after SCT. Patients were enrolled before transplantation and were followed at regular intervals. They completed baseline demographics, medical history, blood draw, pulmonary function tests and HRQL assessments with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-c30, Short Form-36 (SF-36) and St George Respiratory Questionnaire (SGRQ). After the pre-transplant visit, follow-up visits were timed to be at the regular post-transplant follow-up appointments: day 30, day 60, day 100, 6 months, 1 year, 1.5 years and then yearly.
Survey tools
The survey tools used were the QLQ-c30, SF-36 and SGRQ. The SGRQ was administered at every visit, while the SF-36 and QLQ-c30 were given at pretransplant, day 100, 6 month and yearly visits. Surveys were administered by study personnel during the research visit. These particular survey tools were chosen as they represent tools that were created for different populations that pertain to the patients enrolled in this study. For example, the QLQ-c30 was developed to be cancer specific, the SF-36 is a general HRQL measurement and the SGRQ is a respiratory-specific tool.
The QLQ-c30 (v3) is a validated 30-question survey that was developed by the EORTC specifically for cancer patients. 18 It covers five functional scales(physical, role, cognitive, emotional and social) in addition to three symptom scales (fatigue, insomnia and nausea/vomiting). In addition, it includes five single items addressing common symptoms experienced by cancer patients. Global health (QL2) and quality of life questions are also included in the survey tool. Subjects respond to functional and symptom questions using a 4-point Likert scale ranging from '1-Not at All' to '4-Very Much'. Subjects rate their perceived global health and quality of life on a 7 point Likert scale ranging from '1-Very poor' to '7-Excellent'. Subject scores are then transformed into a scale of 0-100. Higher scores on the functional or global health status items correlate with a better quality of life. 18 Higher score for a symptom item correlates with a high level of symptoms or worse quality of life. 18 The SF-36 is a general survey of physical and emotional health that is now the most commonly used in all registered clinical trials internationally. 19 It is a frequently used and well established tool in the SCT population. It consists of 36 questions covering the following eight domains: physical functioning, role-physical functioning, bodily pain, general health, vitality, social functioning, role-emotional functioning and mental health. Composite scores for mental and physical health are generated (MCS and PCS). Subjects respond to questions using a mix of yes/no and Likert scale formats. Scores are transformed to a scale of 0-100 with higher scores representing a better quality of life. 20 The SGRQ was developed for patients with asthma and COPD 21 but has also been used in patients with bronchiectasis 22 and sarcoidosis. 23 It contains 76 questions that cover three components including: symptoms, activities and impacts. 24 Subjects respond to questions using a mix of yes/no, true/false and Likert formats. The symptom scores component describes the subject's perception of the frequency, severity and effect that their respiratory symptoms have had over the preceding 3 months. The activity score is generated by questions addressing the activities that cause or limit a subject in their current state. The impact score is the broadest and covers questions regarding the subject's perception of how their respiratory disease affects their psychosocial health. A total score is generated in addition to individual component scores. The score is expressed on a scale of 0-100 with higher scores representing a worse quality of life. 24 
Analysis
For HRQL data, patients were analyzed in three groups at 6 months, 1 year and 2 years after transplant. The three groups were: (1) No or mild cGVHD and no BOS; (2) Moderate or severe cGVHD and no BOS; and (3) Moderate or severe cGVHD and BOS. Scoring of cGVHD was performed using the NIH consensus definitions. 25 BOS was defined using the International Society for Heart and Lung Transplantation diagnostic criteria for BOS stage 1 disease including a persistent drop in FEV1 by 420% from baseline in the presence of airflow obstruction defined as FEV1/FVColower limit of normal and without other cause. 26 
Statistical analysis
Demographic and clinical characteristics are presented as frequencies and percentages for categorical variables while continuous variables are presented as means and s.d. Fisher's exact method was used to test for differences in percentages across the three groups and analysis of variance was used to compare means across groups. Random-effects linear regression was used to estimate mean HRQL scores along with their associated 95% confidence intervals due to the longitudinal nature of the observations. The regression model included group, continuous time in years and the interaction between group and time. Also included were random intercept and slope terms along with unstructured covariance. The mean HRQL scores (including 95% confidence interval) were then plotted over time. The analysis was adjusted for age, gender and relapse status without change in the results. All statistical analyses were run using Stata 12.1, Stata Corporation, College Station, TX, USA.
RESULTS
Study completion
There was a total of 245 pre-transplant patients enrolled into the study. Twenty-two patients did not go on to receive a transplant so were not included in the analysis. Figure 1 shows number of subjects included at each time point. If patients declined to complete HRQL surveys due to relapse or hospitalization they were included in the withdrawn group. Only subjects with at least 6 months of data were included in the analysis of HRQL. Quality of life measures were compared between patients who had relapsed disease compared with those without and there was no statistical difference between the two groups. For this reason, all patients, including those that relapsed were included in the analysis.
At baseline and 6 months, there was a total of 126 patients included (71 in group 1 (no or mild cGVHD and no BOS), 32 in group 2 (moderate or severe cGVHD and no BOS) and 23 in group 3 (moderate or severe cGVHD and BOS)). At 1 year, there was a total of 94 patients included (47 patients in group 1, 27 patients in Quality of life in bronchiolitis obliterans syndrome EN Amin et al group 2 and 20 patients in group 3). At 2 years, there was a total of 49 patients (24 patients in group 1, 13 patients in group 2 and 12 patients in group 3). Response rates at each time point analyzed are as follows: 96% before transplantation, 81% at 6 months, 73% at 1 year and 76% at 2 years. The median time to developing BOS was 487 days while the median time to develop cGVHD was 365 days.
Baseline demographics There was a total of 71 patients who were eventually classified in group 1 (no or mild cGVHD and no BOS), 32 patients in group 2 (moderate or severe cGVHD and no BOS) and 23 patients in group 3 (moderate or severe cGVHD and BOS). Demographics are seen in Table 1 . The majority of transplants were PBSCTs following reduced-intensity conditioning. The vast majority of recipients were white with a slight predominance of males. There were few statistically significant differences between the groups. Notably, there was a statistically significant increase in the proportion of patients with a history of pulmonary disease that developed BOS (group 3). There were also significant differences between the groups in regards to the type of transplant and whether T-cell depletion with anti-thymocyte globulin was used. As expected, Comorbidity Index Score calculated using the Sorror hematopoietic comorbidity index measured before transplantation. c Acute and chronic GVHD were reported as the highest severity that the patient reached at any time point during the study period.
there were significantly more patients in the no or mild cGVHD group that received T-cell depleted transplants. In addition, there was a significantly higher number of subjects with related transplants in the group that developed moderate or severe cGVHD without BOS (group 2).
Health-related quality of life The mean HRQL scores for all study participants with at least 6 months of data are shown in Figure 2 . There was no statistically significant change in HRQL over time measured by the QLQ-C30 global health score (Figure 2a ). HRQL statistically improved over time when measured by the SF-36 PCS and SF-36 MCS with P = 0.007 and P o0.001, respectively (Figure 2a) . SGRQ impact and symptom scores showed higher scores over time, indicating worse perceived quality of life with P = 0.028 and P = 0.047, respectively (Figure 2b ). There was no significant change in the SGRQ activity score or the SGRQ total score over time (Figure 2b) . Figure 3a shows the linear regression comparing the HRQL between the three groups measured by the QLQ-c30 global health score. Subjects with moderate or severe cGVHD alone (group 2) or those with no or mild cGVHD (group 1) had a trend toward improved global health scores over time. While patients who went on to develop BOS (group 3) had statistically higher global health scores compared with the other two groups, indicating better perceived quality of life before transplant, the group had a decline in global health scores over time. Although the BOS group had global health scores lower than the subjects in the other two groups at the 2-year time point, this was not statistically significant.
The subscales of the QLQ-c30 were analyzed (not shown). Patients who developed BOS (group 3) did have a trend toward significantly worse dyspnea compared with those with no or mild cGVHD alone (group 1) at 2 years (P-value 0.053). There were no other differences in the dyspnea symptom scores across the groups. Emotional function was also found to be significantly worse in patients with BOS (group 3) before transplant and at 6 months compared with patients with no or mild cGVHD alone (group 1) with P = 0.044 and P = 0.041, respectively. This difference was not seen at 1 or 2 years.
Figures 3b and c show the comparison of the SF-36 PCS and MCS between the three groups. Overall, it appears that those with no or mild cGVHD and no BOS (group 1) have an improvement in their PCS scores over time, while the other groups have stable scores over time. At 2 years, patients who developed BOS (group 3) had statistically significantly worse PCS scores compared with those with no or mild cGVHD and no BOS (group 1; P-value 0.046). The differences observed in PCS scores between those with moderate or severe cGVHD without BOS (group 2) and those with no or mild cGVHD (group 1) were not statistically significant. In addition, there was no difference in patients with BOS and moderate or severe cGVHD compared with patients with moderate or severe cGVHD without BOS. There were no statistically significant differences in HRQL scores between the three groups using the SF-36 MCS at any time point.
The subscales of the SF-36 were analyzed (not shown) and showed no significant differences across the groups except for general health. Patients with moderate or severe cGVHD had significantly worse general health scores before transplant, 6 months and 1 year after transplant compared with those with no or mild cGVHD with P = 0.036, P = 0.007 and P = 0.045, respectively. This difference was not seen at 2 years. The BOS group did not demonstrate any difference in general health scores when compared with the other groups. Figure 4 shows HRQL scores for the three groups for the separate components of the SGRQ including: activity, impacts, symptoms and total scores. Figure 4a shows that for the SGRQ activity component, patients with BOS (group 3) had significantly worse activity scores when compared with patients with no or mild cGVHD and no BOS (group 1) at year 1 and 2 (P = 0.008 and P = 0.001, respectively). When compared with patients with moderate or severe cGVHD without BOS (group 2), patients with BOS (group 3) also had worse activity scores at year 1 and 2 (P = 0.017 and P = 0.001, respectively). In patients without BOS, there were no significant differences based on the presence or absence of cGVHD. Figure 4b shows similar results for the SGRQ impact component. While there was no significant difference in scores between groups before transplant or at 6 months after transplant, patients that developed BOS (group 3) did have significantly worse impact scores at 1 and 2 years after transplant compared with those without BOS and no or mild cGVHD (group 1) with P = 0.027 and P = 0.014, respectively. Subjects in group 3 also had significantly worse impact scores compared with group 2 at year 2 with a trend toward significance at year 1 (P = 0.016 and P = 0.053, respectively). Again, for patients without BOS, there were no differences in impact scores when comparing subjects in group 1 and 2.
The SGRQ symptom component scores are shown in Figure 4c . There were no statistically significant differences between the groups at any time point for the symptom component.
The total score for the SGRQ are similar to the findings on the activity and impact components (Figure 4d ). Patients who developed BOS (group 3) had significantly worse scores compared with patients with no BOS and no or mild cGVHD (group 1) at year 1 and 2 (P = 0.024 and P = 0.003n respectively). They also had significantly worse total scores compared with group 2 at year 2 with a trend toward significance at year 1 (P = 0.007 and P = 0.055, respectively). There were no statistically significant differences between the two groups without BOS at any time point.
DISCUSSION
BOS remains a devastating and important long term complication following SCT. HRQL has been shown to be effected by multiple factors following SCT including cGVHD. This is the first study to our knowledge to examine the impact on HRQL in patients that develop BOS following SCT.
Overall, our study population had fairly well-matched demographics across the three groups. However, there are a couple of notable differences. First, there was a statistically significantly higher number of patients in group 1 who received T-cell depleted transplants with anti-thymocyte globulin. Given that T-cell depletion is associated with reduced rates of cGVHD, this is expected. Interestingly, there was a significantly higher number of patients who developed moderate or severe cGVHD following a related donor transplant compared with unrelated donor. This is somewhat unexpected as cGVHD is thought to be decreased in patients receiving a related donor transplantation, but could be due to our institutional practice of omitting anti-thymocyte globulin for patients undergoing a matched related donor transplant. Patients in the BOS group did have a significantly higher rate of pre-transplantation pulmonary disease compared with the other groups. Further study is needed to determine if this is a significant risk factor for the development of BOS after SCT.
With regard to HRQL, our overall study group showed mixed results over time with improved HRQL that was statistically significant when using the SF-36 as the measurement survey but stable with the QLQ-c30. However, patients reported increased respiratory symptoms and impact over time on the SGRQ. It has previously been published that HRQL improves following transplant ,6-8 but fails to reach population normals. [7] [8] [9] [10] Our group demonstrated stable to improved HRQL over time but was not compared with a normal population. Instead, our group was compared based on the development of cGVHD and/or BOS.
Our study demonstrated multiple interesting findings regarding the impact of developing BOS on HRQL. Patients who developed BOS were demonstrated to have worse HRQL on several of the survey components. Interestingly, patients with BOS did not report significantly higher symptom scores on the SGRQ compared with the other two groups. Dyspnea was worse in patients with BOS measured on the QLQ-c30 symptom score but was only borderline statistically significant. Despite this lack of significant symptom difference, the development of BOS does seem to negatively impact physical functioning and ability to perform activities based on the SF-36 PCS and SGRQ activity component score. In addition, the detrimental psychosocial impact of their disease was represented by the worse SGRQ impact component compared with other groups. These findings did not appear to be attributable to the severity of cGVHD alone as patients with moderate or severe cGVHD did not have a difference in scores when compared with those with no or mild cGVHD for these scales.
It is not surprising that patients with BOS following SCT have worse HRQL scores on the SGRQ. This questionnaire has also been shown to be validated in other respiratory diseases including COPD, 18 asthma 21 and bronchiectasis. 22 The SGRQ has also been used to evaluate HRQL in patients with sarcoidosis. 23 At least one study has examined the impact on HRQL measured by the SGRQ in patients who developed BOS following lung transplantation. It was found that patients who developed BOS following lung transplantation had significantly worse HRQL scores compared with those without BOS. 15 We compared HRQL scores between patients with relapsed disease and those without relapsed disease and did not find a significant difference, which was somewhat surprising as we would expect relapse to significantly impact an individual's HRQL. This may relate to the timing of their relapse and survey administration. Another interesting finding is that there were no detectable differences in HRQL scores when comparing cGVHD status after removing those patients with BOS. CGVHD has been reported to be a factor affecting HRQL, which was not replicated in our population. [11] [12] [13] This may in part be attributable to the fact that patients with BOS and cGVHD were analyzed separately from the other moderate to severe cGVHD groups, which was not necessarily the case in other studies.
There are limitations of our study to note. The most significant limitation is that our patient numbers drop significantly as time goes on due to a high dropout rate from the study. This has been noted as a limitation in other studies evaluating HRQL following SCT. 27 This may have led to bias as to which patients remained in the study and completed the surveys. This may have also affected the results of our year 2 time point. However, the results were comparable to previous time points so were felt to be valid and were included in the results. Another limitation is that the data were analyzed comparing groups based on whether they eventually developed BOS and based on the highest severity cGVHD that developed during the study time. Patients with BOS and cGVHD experience exacerbations of their disease, and depending on their status at the time of the survey this may have affected the responses. However, the aim of this study was to examine the global impact of BOS on HRQL rather than during specific exacerbations so the grouping of patients was felt to be appropriate.
In summary, our findings show that HRQL is negatively impacted by the development of BOS following allo-SCT independent of cGVHD status. The SGRQ demonstrated the largest effect when comparing the HRQL of patients who developed BOS and those that did not after transplant. Further research is needed to determine if specific screening questions could diagnose BOS earlier, which could have significant impact on the disease course.
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